Modeyso (Dordaviprone / ONC201): A Complete Guide to H3 K27M-Mutant Glioma Treatment

Modeyso (Dordaviprone / ONC201)

Introduction

Modeyso (generic name: Dordaviprone, also called ONC201) is a breakthrough therapy designed for patients with H3 K27M-Mutant glioma, an aggressive and hard-to-treat brain and spinal cord tumor. Traditional treatments such as surgery and radiotherapy often fail to control this type of cancer.

On August 6, 2025, the U.S. Food and Drug Administration (FDA) approved Modeyso, making it the first targeted drug available for both adults and children (≥1 year old) diagnosed with this rare glioma mutation.

What is Modeyso (Dordaviprone / ONC201)?

• Pronunciation: moh-DAY-soh
• Generic Name: Dordaviprone
• Also Known As: ONC201
• Formulation: 125 mg oral capsules

Modeyso is marketed by Jazz Pharmaceuticals, after being originally developed by Chimerix.

Medical Uses of Modeyso

Modeyso is prescribed for:

• Treatment of H3 K27M-Mutant glioma in the brain or spinal cord.
• Patients who do not respond to surgery or radiation therapy.
• Pediatric and adult patients (from 1 year of age).

By interfering with cancer cell survival mechanisms, Modeyso helps slow down tumor progression and trigger cancer cell death.

How Modeyso Works (Mechanism of Action)

Modeyso (Dordaviprone / ONC201) works through multiple pathways:

1. ClpP activation in mitochondria → destroys damaged proteins inside tumor cells, leading to apoptosis (cell death).
2. Blocking dopamine D2 receptors → disrupts tumor growth signals.
3. Inhibiting PI3K/Akt and MAPK/ERK signaling pathways → prevents uncontrolled tumor cell division.

This dual action makes Modeyso unique compared to standard treatments.

Dosage Forms and Administration

• Available as 125 mg oral capsules.
• Capsules may be opened and mixed with 15–30 ml of water or apple juice for patients unable to swallow.

Modeyso Dosage Guidelines

Adults

• 625 mg once weekly on an empty stomach.
• If vomiting occurs, do not retake the dose. Wait until the next scheduled weekly dose.

Children (Weight-Based Dosing)

Body Weight (kg)	Recommended Dose
10–12.5	125 mg
12.5–27.5	250 mg
27.5–42.5	375 mg
42.5–52.5	500 mg
≥52.5	625 mg

💡 Tips:

• Take Modeyso on an empty stomach for better absorption.
• If more than two days are missed, skip and resume the regular schedule.

Clinical Trial Results for Modeyso

Key findings from studies on Modeyso include:

• Overall Response Rate (ORR): 22%
• Median Duration of Response (DOR): 10.3 months
• Responses lasting ≥6 months: 73%
• Responses lasting ≥12 months: 27%

These results show Modeyso significantly improves survival and disease control in patients with H3 K27M-Mutant glioma.

Modeyso Side Effects

Common Side Effects:

• Fatigue
• Headache
• Nausea or vomiting
• Muscle and joint pain

Laboratory Changes:

• Low white and red blood cells
• Low calcium levels
• Elevated liver enzymes

Serious Side Effects:

• Severe allergic reactions
• QTc prolongation (irregular heart rhythm)
• Possible fertility impairment

 Learn more about: Keytruda (Pembrolizumab): Effective Cancer Immunotherapy Option

Warnings and Precautions

• Pregnancy & breastfeeding: Perform a pregnancy test before starting Modeyso. Use contraception during treatment. Do not breastfeed during treatment and for one week after the last dose.
• Heart conditions: ECG monitoring is recommended in patients at risk for arrhythmia.
• Fertility: May negatively affect fertility in men and women.
• Drug interactions: Avoid strong CYP3A4 inducers/inhibitors and QTc-prolonging drugs.

Drug Interactions with Modeyso

• CYP3A4 inhibitors: May require dose adjustment.
• CYP3A4 inducers: Should be avoided.
• QTc-prolonging medicines: Use only under medical supervision.

FDA Approval, PDUFA, and Jazz Pharmaceuticals

• FDA Approval Date: August 6, 2025.
• PDUFA Date: August 18, 2025.
• Developed by: Chimerix.
• Marketed by: Jazz Pharmaceuticals.

Storage Instructions

• Store at room temperature (20–25 °C).
• Supplied in child-resistant bottles.

Composition of Modeyso

• Active Ingredient: Dordaviprone.
• Inactive Ingredients: Magnesium stearate, microcrystalline cellulose, sodium starch glycolate, hypromellose, titanium dioxide, coating agents, printing ink.

FAQs about Modeyso (Dordaviprone / ONC201)

1. What is Modeyso used for?

Modeyso is used to treat patients with H3 K27M-Mutant glioma that affects the brain or spinal cord, especially when surgery or radiation are ineffective.

2. How does Modeyso work?

It activates mitochondrial enzymes (ClpP), blocks dopamine D2 receptors, and inhibits tumor cell growth pathways.

3. Is Modeyso safe for children?

Yes, Modeyso is FDA-approved for children aged one year and older, with weight-based dosing.

4. What is the FDA approval date for Modeyso?

Modeyso was officially approved by the FDA on August 6, 2025.

5. What are the most common side effects?

The most reported side effects include fatigue, headache, nausea, vomiting, and muscle pain.

Conclusion

Modeyso (Dordaviprone / ONC201) is a game-changing therapy for H3 K27M-Mutant glioma. With FDA approval and strong clinical trial data, it represents a new hope for patients and families facing this aggressive brain tumor.

• Proven effectiveness in adults and children.
• Weekly dosing schedule makes it convenient.
• Requires careful monitoring of side effects and interactions.

👉 Always consult your doctor before starting Modeyso to ensure safe use and the right dosage.